X
API Suppliers
0
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
0
Other Suppliers
0
0
0
USA (Orange Book)
0
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
USFDA Orange Book Patents
0
USFDA Exclusivities
0
Blog #PharmaFlow
0
News
EDQM
0
USP
0
JP
0
Other Listed Suppliers
0
0
Details:
Under the terms of the agreement, XOMA has acquired all rights to ebopiprant held by ObsEva, including the Organon/ObsEva license agreement and the IP associated with the asset.
Lead Product(s): Ebopiprant
Therapeutic Area: Obstetrics/Gynecology (Women’s Health) Product Name: OBE022
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: XOMA
Deal Size: $490.0 million Upfront Cash: $15.0 million
Deal Type: Acquisition November 22, 2022
Details:
Ebopiprant is an investigational, orally active, selective prostaglandin F2α (PGF2α) receptor antagonist being evaluated as a potential treatment for preterm labor by reducing inflammation and uterine contractions.
Lead Product(s): Ebopiprant
Therapeutic Area: Obstetrics/Gynecology (Women’s Health) Product Name: OBE022
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Organon
Deal Size: $1,000.0 million Upfront Cash: $500.0 million
Deal Type: Licensing Agreement July 27, 2021
Details:
Ebopiprant, when administered with atosiban infusion to women with preterm labor, reduced delivery in singleton pregnancies at 48 hours after the start of dosing by over 50% compared to atosiban alone.
Lead Product(s): Ebopiprant
Therapeutic Area: Obstetrics/Gynecology (Women’s Health) Product Name: OBE022
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 10, 2021
Details:
In the PROLONG study, ebopiprant reduced delivery in singleton pregnancies at 48 hours after the start of dosing by 55% compared to atosiban alone. Overall, 12.5% of women receiving ebopiprant delivered within 48 hours of starting treatment compared to placebo.
Lead Product(s): Ebopiprant
Therapeutic Area: Obstetrics/Gynecology (Women’s Health) Product Name: OBE022
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 16, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
